Researchers collaborate on first-in-human study of novel malaria vaccine

May 31, 2017, Instituto de Medicina Molecular
P. berghei parasite multiplying inside a liver hepatocyte and presenting at the interface with the host cell, the major antigen, the circumsporozoite protein. Credit: Miguel Prudêncio lab, iMM Lisboa

An international research collaborative is testing a new approach to malaria vaccine development in humans for the first time. The concept is similar to that used by Edward Jenner to develop a vaccine against smallpox, the only disease affecting humans that has ever been eradicated. Jenner used cowpox, a much less dangerous bovine version of the disease, to inoculate people against smallpox. In this clinical trial, based on data from earlier animal studies conducted by iMM Lisboa, the researchers will use a rodent version of the malaria-causing parasite (Plasmodium berghei) to determine if it can induce protection against infection by Plasmodium falciparum, the deadliest version of the parasite that infects humans.

In the study, a specific gene from P. falciparum known as the circumsporozoite protein (CS), will be inserted into the rodent parasite, resulting in a genetically modified version known as Pb(PfCS@UIS4). By inserting the gene for CS, the researchers hope to improve the potential of the modified rodent parasite to induce a protective response in healthy human volunteers.

"Bringing together the concept underlying the first vaccine ever developed, combined with modern genetic manipulation tools, is a truly innovative approach to vaccination," said Miguel Prudêncio, who is leading the research team at iMM Lisboa.

The trial will be conducted in two phases at Radboudumc in the Netherlands. In the first phase, 18 healthy adult volunteers will be recruited into three groups and exposed to a varying, but carefully controlled number of bites from mosquitoes infected with the genetically modified P. berghei parasite. The researchers will closely monitor volunteers for signs of infection to make sure they are treated if they become ill. If all goes well in the Phase 1 study, volunteers from the highest dose group will enter the second phase of the study, which is designed to assess protective efficacy of the approach.

A P. berghei sporozoite (the infective Plasmodium parasite form injected by mosquitoes in the mammalian skin) sheds its major antigen, the circumsporozoite protein, during its gliding movement to reach a liver cell. Credit: Miguel Prudêncio lab, iMM Lisboa

"This is the first time we have tested a genetically modified malaria vaccine approach in Europe using this rodent parasite," said Robert Sauerwein, principal investigator and professor of medical parasitology at Radboudumc. "Along with our partners in the Netherlands, the Havenziekenhuis and Erasmus MC, we're looking forward to investigating whether this novel concept might one day contribute to the elimination and eradication of this terrible disease."

Malaria killed more than 429,000 people in 2015, most of them young African children. Although the most advanced vaccine in development globally is slated for pilot implementation in parts of Africa beginning in 2018—an incredible accomplishment and critically important step—researchers are still on the hunt for a malaria vaccine that can confer higher levels of durable efficacy. The long-term goal of the community, as outlined in the World Health Organization's Malaria Vaccine Technology Roadmap, is to develop vaccines with protective efficacy of at least 75 percent against clinical malaria, and vaccines that reduce transmission of the parasite in order to lower the incidence of .

"Although much progress has been made to drive down the malaria burden with currently available interventions, a highly effective would be an important new tool for ," said Ashley Birkett, director of PATH's Malaria Vaccine Initiative (MVI). "We are pleased to collaborate with Radboudumc and iMM Lisboa on testing this novel approach."

Explore further: Modified experimental vaccine protects monkeys from deadly malaria

Related Stories

Modified experimental vaccine protects monkeys from deadly malaria

May 22, 2017
Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, modified an experimental malaria vaccine and showed that it completely protected four of eight ...

Experimental vaccine protects against multiple malaria strains

February 20, 2017
An experimental malaria vaccine protected healthy subjects from infection with a malaria strain different from that contained in the vaccine, according to a study published today in the Proceedings of the National Academy ...

Malaria elimination: Vaccines should be tested on larger groups of volunteers

January 12, 2017
To find an effective vaccine against malaria it is crucial to test candidate vaccines on larger groups of people than previously thought - according to a new study published in PLOS Computational Biology. The researchers ...

Mosquito bites deliver potential new malaria vaccine

September 11, 2013
This study suggests that genetically engineered malaria parasites that are stunted through precise gene deletions (genetically attenuated parasites, or "GAP") could be used as a vaccine that protects against malaria infection. ...

Scientists devise novel way to predict efficacy of malaria vaccines

February 13, 2017
The acid test for a vaccine is: "Does it protect people from infection?" Emory Vaccine Center researchers have analyzed this issue for a leading malaria vaccine called RTS,S, and their results have identified candidate signatures, ...

Recommended for you

Scientists gain new insight on how antibodies interact with widespread respiratory virus

February 22, 2018
Scientists have found and characterized the activity of four antibodies produced by the human immune system that target an important protein found in respiratory syncytial virus (RSV), according to new research published ...

Study reveals how kidney disease happens

February 22, 2018
Monash researchers have solved a mystery, revealing how certain immune cells work together to instigate autoimmune kidney disease.

Past encounters with the flu shape vaccine response

February 20, 2018
New research on why the influenza vaccine was only modestly effective in recent years shows that immune history with the flu influences a person's response to the vaccine.

Building better tiny kidneys to test drugs and help people avoid dialysis

February 16, 2018
A free online kidney atlas built by USC researchers empowers stem cell scientists everywhere to generate more human-like tiny kidneys for testing new drugs and creating renal replacement therapies.

Study suggests expanded range for emerging tick-borne disease

February 16, 2018
Human cases of Borrelia miyamotoi, a tick-borne infection with some similarities to Lyme disease, were discovered in the eastern United States less than a decade ago. Now new research led by the Yale School of Public Health ...

Expanding Hepatitis C testing to all adults is cost-effective and improves outcomes

February 16, 2018
According to a new study, screening all adults for hepatitis C (HCV) is a cost-effective way to improve clinical outcomes of HCV and identify more infected people compared to current recommendations. Using a simulation model, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.